View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 28, 2021

Pieris receives funding to develop drug for long Covid treatment

Pieris will present PRS-220’s preclinical data this year and start clinical development next year.

US-based Pieris Pharmaceuticals has received a funding grant to develop PRS-220 to treat post-acute sequelae of SARS-CoV-2 infection (PASC) pulmonary fibrosis (PASC-PF), also called post-Covid-19 syndrome pulmonary fibrosis or long Covid.

The $17m (€14.2m) grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy will support the research and development of PRS-220.

PRS-220 is an oral inhaled Anticalin protein that inhibits connective tissue growth factor (CTGF). Pieris developed the drug for idiopathic pulmonary fibrosis (IPF).

CTGF is associated with remodelling due to an abnormal wound healing process. IPF patients are known to have elevated expression of this protein in lung tissue.

According to the company, clinical data show CTGF inhibition could lower the weakening of lung function among this patient population.

The role of CTGF in fibrosis and its expression on tissue injury and fibrotic remodelling makes it a target for PASC-PF intervention.

Some patients experience persistent symptoms after severe Covid-19, including a decline in lung function and interstitial lung abnormalities that suggest tissue impairment similar to fibrosis.

A proportion of these patients are anticipated to benefit from an anti-fibrotic drug such as PRS-220. PASC-PF currently lacks approved treatment.

Pieris plans to start clinical development of PRS-220 for long Covid, as well as IPF next year.

Pieris Pharmaceuticals president and CEO Stephen Yoder said: “We are excited to unveil our most advanced proprietary inhaled respiratory programme and look forward to sharing more details on this programme later this year while actively working to begin clinical development next year.

“Pieris is a pioneer in the inhaled biologics space, and it is gratifying to leverage our respiratory platform to improve the lives of those affected by respiratory diseases such as IPF and Covid-19.”

The Bavarian grant will be leveraged to assess PRS-220 in PASC-PF patients.

It will also be used for clinical-readiness activities, initial clinical development in the post-Covid-19 setting, which includes GLP tox studies and GMP manufacturing and Phase I development.

Pieris expects to present PRS-220’s preclinical data in the coming months.

Last month, the company partnered with Roche Group subsidiary Genentech to discover, develop and market respiratory and ophthalmology therapies.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU